NCT07418099 External Multicenter Validation of the APTTO Model for Prolonged APTT Using Clot Waveform Analysis
| NCT ID | NCT07418099 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz |
| Condition | Coagulation Disorder, Blood |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2026-01-13 |
| Primary Completion | 2027-03 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Prolonged activated partial thromboplastin time (APTT) is a frequent laboratory finding that may reflect a broad spectrum of underlying conditions, ranging from benign laboratory abnormalities to clinically relevant hemostatic disorders. Clot waveform analysis (CWA), automatically generated during routine APTT testing by optical coagulation analyzers, provides additional quantitative and qualitative information on clot formation dynamics. The APTTO model is a previously developed two-step predictive algorithm based on CWA features designed to estimate the probability of a pathological cause of prolonged APTT and to differentiate lupus anticoagulant from intrinsic pathway factor deficiency or von Willebrand disease. Internal validation has demonstrated good discrimination and calibration. This multicenter observational study aims to perform an external validation of the APTTO model in independent patient cohorts, assessing its discrimination, calibration, and decision-analytic performance without model updating.
Eligibility Criteria
Inclusion Criteria: 1. Patients of any age (pediatric and adult populations) undergoing coagulation testing with: \- Prolonged activated partial thromboplastin time (APTT), defined as an APTT ratio ≥ 1.25. \- Normal prothrombin time (PT), according to local laboratory reference ranges. 2. Availability of clot waveform analysis (CWA) data obtained during routine APTT testing using: * Optical coagulation analyzers (ACL TOP platform). * Silica-based APTT reagent (SynthASil®). 3. Completion of the standard laboratory evaluation for prolonged APTT as part of routine clinical care, when clinically indicated. 4. Samples collected and processed in accordance with the standardized preanalytical protocol defined in the study SOP. 5. Patients evaluated in either: * Preoperative assessment, or * Routine clinical practice (non-preoperative setting). Exclusion Criteria: 1. Prolonged prothrombin time (PT) or combined prolongation of PT and APTT. 2- Inadequate preanalytical conditions, defined as non-